Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Jun 2009 17:09

RNS Number : 7817T
Skyepharma PLC
11 June 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

SkyePharma Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Delta adjustment

X

3. Full name of person(s) subject to the notification obligation: iii

D. E. Shaw & Co., L.P. 

D. E. Shaw & Co. (U.K.), Ltd. 

4. Full name of shareholder(s)  (if different from 3.):iv

N/A

5. Date of the transaction and date on which the threshold is crossed or reached: v

June 9, 2009

6. Date on which issuer notified:

June 11, 2009

7. Threshold(s) that is/are crossed or reached: vi, vii

34%

  

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/  Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Contract for Differences ("CfD") relating to convertible bond due 2024

March 4, 2010

3,083,845

Nominal

Delta

13.25%

CfD relating to convertible bond due 2025

November 30, 2009

2,410,877

Nominal

Delta

10.36%

CfD relating to convertible bond due 2025

June 3, 2010

2,410,877

Nominal

Delta

10.36%

Total (A+B+C)

Number of voting rights

Percentage of voting rights

7,905,599

33.97%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Each of D. E. Shaw & Co., L.P. ("DESCO LP") and D. E. Shaw & Co. (U.K.), Ltd. ("DESCO UK") is notifying solely in its capacity as a discretionary investment manager. As general partner of DESCO LP, D. E. Shaw & Co., Inc. ("DESCO Inc.") is a parent undertaking of DESCO LP and DESCO UK. By virtue of David E. Shaw's position as president and sole shareholder of DESCO, Inc., which is the general partner of DESCO LP, David E. Shaw is a parent undertaking of DESCO LP and DESCO UK.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Stephen Back (Compliance Department)

15. Contact telephone number:

+1 212-478-0000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLQFLFFKQBBBBD
Date   Source Headline
3rd Apr 201411:51 amRNSDirector/PDMR Shareholding
3rd Apr 201411:50 amRNSDirector/PDMR Shareholding
1st Apr 20144:58 pmRNSAnnual Financial Report
31st Mar 20147:45 amRNSProposed Placing and Open Offer to Raise £112m
31st Mar 20147:00 amRNSFinal Results
26th Mar 20147:00 amRNSNotice of Results
6th Mar 20142:44 pmRNSDirector Declaration
5th Mar 20147:00 amRNSBoard Changes
4th Mar 20149:47 amRNSHolding(s) in Company
3rd Mar 20143:38 pmRNSHolding(s) in Company
28th Feb 20147:02 amRNSBoard Change
21st Feb 20142:53 pmRNSAnoro Receives Positive Opinion from CHMP
10th Feb 20145:59 pmRNSHolding(s) in Company
10th Feb 20147:00 amRNSflutiform launched in France
4th Feb 20143:19 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSTrading Update
22nd Jan 20142:50 pmRNSPositive step towards flutiform approval in Spain
19th Dec 20137:45 amRNSANORO ELLIPTA RECEIVES REGULATORY APPROVAL IN US
18th Dec 20132:52 pmRNSUpdate on Lyon manufacturing facility
4th Dec 20137:00 amRNSCapital Markets meeting & flutiform sales update
25th Nov 20135:54 pmRNSDirector/PDMR Shareholding
25th Nov 201310:57 amRNSFurther re Directorate Change
19th Nov 20137:00 amRNSPartner Kyorin launches flutiform in Japan
11th Nov 201311:41 amRNSHolding(s) in Company
11th Nov 201310:42 amRNSDirector/PDMR Shareholding
30th Oct 201311:38 amRNSHolding(s) in Company
10th Oct 20137:00 amRNSInterim Management Statement
24th Sep 20133:39 pmRNSHolding(s) in Company
23rd Sep 20134:31 pmRNSHolding(s) in Company
23rd Sep 20139:31 amRNSHolding(s) in Company
20th Sep 20138:39 amRNSCapital Markets Day, Muttenz, Switzerland
20th Sep 20138:20 amRNSRELVAR ELLIPTA Receives Approval in Japan
20th Sep 20137:00 amRNSflutiform approved in Japan
19th Sep 20132:02 pmRNSHolding(s) in Company
19th Sep 20131:54 pmRNSHolding(s) in Company
19th Sep 20137:00 amRNSflutiform trial for COPD initiated in Europe
22nd Aug 201311:11 amRNSAppointment of Andrew Derodra as CFO
19th Aug 20134:02 pmRNSHolding(s) in Company
15th Aug 20135:20 pmRNSDirector/PDMR Shareholding
15th Aug 20137:00 amRNSHalf Yearly Report
14th Aug 20133:38 pmRNSHolding(s) in Company
1st Aug 20134:08 pmRNSHolding(s) in Company
31st Jul 20139:28 amRNSflutiform recommended for approval in Japan
8th Jul 20137:00 amRNSNotice of Results
20th Jun 201311:00 amRNSflutiform launch in Italy
19th Jun 201312:31 pmRNSHolding(s) in Company
10th Jun 201310:35 amRNSHolding(s) in Company
4th Jun 20134:40 pmRNSSecond Price Monitoring Extn
4th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20137:00 amRNSPresenting at Jefferies 2013 Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.